Clinical Trial Update: Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating neoadjuvant therapy for ovarian cancer using the PARP inhibitor fuzuloparib in combination with apatinib. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fuzuloparib

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING